Breaking News
Investing Pro 0
New Year’s SALE: Up to 40% OFF InvestingPro+ CLAIM OFFER

AstraZeneca resumes UK trials of COVID-19 vaccine halted by patient illness

Stock Markets Sep 12, 2020 01:35PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. FILE PHOTO: A sign at an AstraZeneca site in Macclesfield
 
AZN
-0.70%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

By Michael Holden

LONDON (Reuters) - AstraZeneca (NYSE:AZN) has resumed British clinical trials of its COVID-19 vaccine, one of the most advanced in development, after getting the green light from safety watchdogs, the company said on Saturday.

The late-stage trials of the experimental vaccine, developed with researchers from the University of Oxford, were suspended this week after an illness in a study subject in Britain, casting doubts on an early rollout.

"On 6 September, the standard review process triggered a voluntary pause to vaccination across all global trials to allow review of safety data by independent committees, and international regulators," AstraZeneca said.

It added that safety reviewers had recommended to Britain's Medicines Health Regulatory Authority (MHRA) that it was safe to resume the British trials.

The patient involved in the study had been reportedly suffering from neurological symptoms associated with a rare spinal inflammatory disorder called transverse myelitis.

AstraZeneca, based in Cambridge, said it could not disclose further medical information.

"The Company will continue to work with health authorities across the world and be guided as to when other clinical trials can resume to provide the vaccine broadly, equitably and at no profit during this pandemic," AstraZeneca said.

It declined to elaborate further on when other global trials were expected to restart.

The Serum Institute of India said it would restart its trials once it had permission from the Drugs Controller General of India.

Brazil's health regulator ANVISA said it was awaiting notice from the British MHRA confirming that resumption of trials has been authorized before resuming in Brazil.

The Federal University of Sao Paulo, which is conducting the paused trials, said in a statement that 4,600 of the planned 5,000 volunteers have been recruited and vaccinated without any of them reporting any serious health issues.

Governments around the world are desperate for a vaccine to help end the pandemic, which has caused more than 900,000 deaths and global economic turmoil. The World Health Organization (WHO) had flagged AstraZeneca's as the most promising.

The vaccine is in late-stage clinical trials in the United States, Britain, Brazil and South Africa and additional trials are planned in Japan and Russia.

'WAKE-UP CALL'

The pause of the trials came after reports that the United States was aiming for fast-track authorization or approval of a vaccine before November's presidential election.

Leading U.S. and European vaccine developers have pledged to uphold scientific safety and efficacy standards for their experimental vaccines and not bow to political pressures to rush the process.

AstraZeneca has already agreed to supply close to three billion doses to governments across the globe - more than any other vaccine project.

The WHO's chief scientist said the pause in the trials should serve as a "wake-up" call that there would be ups and downs in the development of a vaccine.

"Inevitably with such a large trial there will be times when safety issues arise," said Peter Openshaw, professor of experimental medicine at Imperial College London.

"We must all hope that there are no future events and that the vaccine proves both safe and effective."

AstraZeneca resumes UK trials of COVID-19 vaccine halted by patient illness
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (3)
Swann Karandikar
Swann Karandikar Sep 13, 2020 1:57AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Get rid of WHO. They have proved that their opinions are worthless. These world organizations are employing politicians as the heads who come from under developed regions where corruption is rampant and taking bribes is only way to survive. They were sleeping at the helm.
Jared Ryan
Jared Ryan Sep 12, 2020 2:04PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
It'll get halted again. They had a ton of severe reactions in animal trials. This vaccine will not get fda approval, mark my words.
Edward Chong
Edward Chong Sep 12, 2020 2:04PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
why are u so sure?
Swann Karandikar
Swann Karandikar Sep 12, 2020 2:04PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
A little 🐦 said so....
Kingy Yu
Kingy Yu Sep 12, 2020 1:27PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Good news!!!
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email